Development and Application of CRISPR Technology in the Treatment of Autoimmune Diseases

Abstract

Autoimmune diseases (ADs) result from the immune system’s misidentification of self-antigens, leading to harmful responses and pathological states. The CRISPR/Cas9 system, a groundbreaking gene-editing technology, offers promising avenues for addressing ADs. Drawing inspiration from prokaryotic immune mechanisms, CRISPR/Cas9 precisely targets and edits foreign DNA, providing unprecedented genome-editing capabilities. Manipulating immune cell genetics or regulating relevant protein expression with CRISPR/Cas9 shows significant therapeutic potential in managing ADs. Recent research and clinical studies emphasize the valuable role of CRISPR/Cas9 in understanding the underlying pathogenic mechanisms of ADs, especially concerning non-viral triggers. Through strategic and targeted approaches, substantial progress is anticipated in comprehending and managing ADs. CRISPR/Cas9 emerges as a safe and efficient tool for tackling a wide range of ADs with diverse etiologies, offering transformative advancements in treatment strategies. This technology holds immense promise in reshaping the landscape of autoimmune disease management, providing hope for improved outcomes and enhanced quality of life for affected individuals.